For decades, women's hormonal cycles were treated as a scientific nuisance rather than a legitimate area of study. Researchers systematically excluded women from clinical trials and basic science experiments to sidestep the "complications" of fluctuating estrogen and progesterone levels. This exclusion left a massive gap in medical knowledge about how hormones affect drug efficacy, disease progression, and treatment outcomes across half the population.
New Scientist reports that attitudes are finally shifting. The scientific community now recognizes that hormonal fluctuations represent real physiological changes with measurable impacts on health and medicine. Excluding women from research didn't eliminate hormones from medicine. It simply meant doctors lacked data on how treatments work differently when hormonal levels vary throughout a menstrual cycle.
This oversight has concrete consequences. Women often report that medications prescribed at standard doses perform differently depending on their cycle phase. Pain medications, psychiatric drugs, and cardiovascular treatments all show variable effectiveness tied to hormonal status. Yet this variation went largely unstudied because female subjects were considered "too variable" compared to men, whose hormone levels remain relatively stable.
The shift toward inclusion represents a recognition that scientific rigor demands understanding the full range of human biology. Including women in research designs and analyzing results by hormonal phase doesn't complicate science. It makes science more complete and more useful.
Women have also historically felt pressured to minimize or hide hormonal symptoms at work and in medical settings, fearing they would be perceived as weak or unreliable. Normalizing conversation about hormonal health reduces stigma and encourages women to advocate for their own medical needs.
Modern research initiatives now explicitly recruit women across all cycle phases and analyze how hormones influence treatment responses. This approach yields better drug development and more personalized medicine. Understanding hormonal fluctuation as a normal biological variable, rather than a confounding problem, opens pathways for treatments tailored to menstr